Genómica traslacional y terapias dirigidas en tumores sólidos
Publicaciones destacadas
-
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
Villacampa, G; Tung, N M; Pernas, S; Pare, L; Bueno-Muino, C;(...)Carey, L A; Mittendorf, E A; Martin, M; Prat, A; Tolaney, S M.Referencia:Annals Of Oncology 2023.
-
An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)
Prat, A; Bardia, A; Curigliano, G; Viale, G; Hammond, MEH;Loibl, S; Tolaney, SM.Referencia:Jama Oncology 2022.
-
Customizing local and systemic therapies for women with early breast cancer: the st. gallen international consensus guidelines for treatment of early breast cancer 2021
H J Burstein; G Curigliano; B Thürlimann; W P Weber; P Poortmans 5;M M Regan; H J Senn; E P Winer; M Gnant; Panelists of the St Gallen Consensus Conference.Referencia:Ann Oncol. 2021.
-
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
Prat, Aleix; Guarneri, Valentina; Pare, Laia; Griguolo, Gaia; Pascual, Tomos;(...)Piacentini, Federico; D'Amico, Roberto; Tagtiapco, Enrico; Parker, Joel S; Conte, Pierfranco.Referencia:Lancet Oncology 2020.
-
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Martinez-Saez, Olga; Chic, Nuria; Pascual, Tomas; Adamo, Barbara; Vidal, Maria;(...)Galvan, Patricia; Rodriguez, Ana Belen; Martinez, Antonio; Munoz, Montserrat; Prat, Aleix.Referencia:Breast Cancer Research 2020.
-
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Braso-Maristany, Fara; Griguolo, Gaia; Pascual, Tomas; Pare, Laia; Nuciforo, Paolo;(...)Gomis, Roger R; Villagrasa, Patricia; Cortes, Javier; Ciruelos, Eva; Prat, Aleix.Referencia:Nature Communications 2020.
-
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
Prat, Aleix; Saura, Cristina; Pascual, Tomas; Hernando, Cristina; Munoz, Montserrat;(...)Lopez, Rafael; Celiz, Pamela; Ciruelos, Eva; Villagrasa, Patricia; Gavila, Joaquin.Referencia:Lancet Oncology 2020.